Clinical Scorecard: Investigation of the Development of Lower Urinary Tract Symptoms in Patients with Multiple Sclerosis
At a Glance
Category
Detail
Condition
Multiple sclerosis (MS) with lower urinary tract symptoms (LUTS)
Key Mechanisms
Chronic demyelinating, inflammatory, degenerative disease causing neurological impairment leading to LUTS
Target Population
Adult patients diagnosed with MS according to McDonald’s criteria
Care Setting
Multidisciplinary Center for Diagnostics and Treatment of MS
Key Highlights
Prevalence of LUTS in patients with MS ranges from 32% to 96.8%, with 61% prevalence observed in this cohort.
Median time to onset of LUTS after MS diagnosis is 8 years; 5-, 10-, and 20-year LUTS-free survival rates are 60%, 45%, and 20%, respectively.
Urgency is the most common first LUTS symptom, reported in 51% of patients with LUTS.
Guideline-Based Recommendations
Diagnosis
Use McDonald’s criteria (2017) for MS diagnosis.
Assess LUTS via structured patient interviews and cross-check with medical records including EDSS bladder sub-scores.
Management
Monitor patients regularly for development of LUTS starting from MS diagnosis.
Consider early identification of risk factors such as higher age, higher EDSS, presence of cerebellar/pyramidal symptoms, and oligoclonal bands.
Monitoring & Follow-up
Use Expanded Disability Status Scale (EDSS) including bladder symptom sub-scores at each visit.
Perform structured interviews to track onset and progression of LUTS.
Risks
Higher age at MS diagnosis, higher disability (EDSS), presence of cerebellar and/or pyramidal symptoms, and presence of oligoclonal bands in cerebrospinal fluid are associated with earlier onset of LUTS.
Patient & Prescribing Data
Adult patients with confirmed MS diagnosis under routine follow-up
Early recognition of LUTS and associated risk factors can guide timely management to reduce impact on quality of life.
Clinical Best Practices
Conduct structured in-person interviews to identify LUTS and their onset relative to MS diagnosis.
Cross-validate patient-reported symptoms with medical records to ensure accuracy.
Use Kaplan-Meier analysis to understand LUTS-free survival and inform prognosis.
Incorporate assessment of cerebellar/pyramidal symptoms and cerebrospinal fluid analysis in risk stratification.
